Your browser doesn't support javascript.
loading
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Zuazo, Miren; Arasanz, Hugo; Fernández-Hinojal, Gonzalo; García-Granda, Maria Jesus; Gato, María; Bocanegra, Ana; Martínez, Maite; Hernández, Berta; Teijeira, Lucía; Morilla, Idoia; Lecumberri, Maria Jose; Fernández de Lascoiti, Angela; Vera, Ruth; Kochan, Grazyna; Escors, David.
Afiliação
  • Zuazo M; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Arasanz H; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Fernández-Hinojal G; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • García-Granda MJ; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Gato M; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Bocanegra A; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Martínez M; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Hernández B; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Teijeira L; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Morilla I; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Lecumberri MJ; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Fernández de Lascoiti A; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Vera R; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Kochan G; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Escors D; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
EMBO Mol Med ; 11(7): e10293, 2019 07.
Article em En | MEDLINE | ID: mdl-31273938
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Imunidade Celular / Memória Imunológica / Imunoterapia / Neoplasias Pulmonares / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: EMBO Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD4-Positivos / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Imunidade Celular / Memória Imunológica / Imunoterapia / Neoplasias Pulmonares / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: EMBO Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido